SCHEMBL7344739

SCHEMBL7344739

N=C(N)c1ccc2cc(OC(=O)Cc3ccccc3)ccc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 8/20 0.68
F2 P00734 4/20 0.51
PLG P00747 4/20 0.51
KLK1 P06870 4/20 0.51
PRSS1 P07477 4/20 0.51
KLKB1 P03952 2/20 0.51
F12 P00748 4/20 0.51
TMPRSS2 O15393 1/20 0.51
MLNR O43193 1/20 0.51
ALDH1A1 P00352 1/20 0.51
C1R P00736 1/20 0.51
F10 P00742 1/20 0.51
LMNA P02545 1/20 0.51
ITGB3 P05106 1/20 0.51
HPN P05981 1/20 0.51
CHRM2 P08172 1/20 0.51
ITGA2B P08514 1/20 0.51
C1S P09871 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7339708 0.93 PLAU (0.60) PLAUF2PLGKLK1PRSS1
SCHEMBL7348627 0.87 PLAU (0.60) PLAUF2PLGKLK1PRSS1
SCHEMBL7347825 0.85 PLAU (0.58) PLAUF2PLGKLK1PRSS1
SCHEMBL7347409 0.83 PLAU (0.52) PLAUF2PLGKLK1PRSS1
SCHEMBL7341600 0.81 FTO (0.54) PLAUF2PLGKLK1PRSS1
SCHEMBL7337750 0.80 F12 (0.71) PLAUF2PLGKLK1PRSS1
SCHEMBL31499213 0.79 F12 (0.61) PLAUF2PLGKLK1PRSS1
SCHEMBL7347056 0.79 FTO (0.53) PLAUF2PLGKLK1PRSS1
Methane SCHEMBL11282601 0.79 F2 (0.58) PLAUF2PLGKLK1PRSS1
SCHEMBL10934547 0.78 F12 (0.53) PLAUF2PLGKLK1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170020838-A1 TREATMENT FOR RESPIRATORY DISEASE MUCOKINETICA LIMITED (GB) 2017-01-26 US disclosed
US-20100092402-A1 TREATMENT OF RESPIRATORY DISEASE MUCOKINETICA LTD. (GB) 2010-04-15 US disclosed
EP-0048433-B1 NOVEL AMIDINE COMPOUNDS, PROCESS FOR PRODUCING SAME AND ANTI-COMPLEMENT AGENT COMPRISING THEM TORII & CO., LTD. (JP) 1986-05-28 EP disclosed
US-4532255-A Amidine compounds and anticomplement agent comprising same TORII & CO., LTD. (JP) 1985-07-30 US disclosed
US-4454338-A 6-AMIDINO-2-NATHTHYL-4-GUANIDINOBENZOATE TORII & CO., LTD. (JP) 1984-06-12 US disclosed
EP-0048433-A2 Novel amidine compounds, process for producing same and anti-complement agent comprising them TORII & CO., LTD. (JP) 1982-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100092402-A1 TREATMENT OF RESPIRATORY DISEASE OAT, HRH2, PAM PLAU 454/4885F2 198/4885PLG 608/4885
US-20170020838-A1 TREATMENT FOR RESPIRATORY DISEASE NUDT1, CFTR, P2RY4 PLAU 1762/4885F2 2007/4885PLG 2568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.